A Phase 1 Dose-Escalation Study of LY2940680 in Patients With Advanced Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Nov 2016
At a glance
- Drugs Taladegib (Primary)
- Indications Advanced breast cancer; Basal cell cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly; Ignyta
- 08 Nov 2016 Planned End Date changed from 1 May 2016 to 1 May 2017.
- 19 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 May 2016 as per ClinicalTrials.gov record.
- 19 Jan 2016 Status changed from completed to active, no longer recruiting as per ClinicalTrials.gov record.